Selecting CROs Across the US and Australia for a Phase 2 CNS Study
Summary
A small biotech was preparing for a Phase 2 orphan disease CNS study and needed to select the CRO partner, or combination of partners, that could best support the trial.
The sponsor wanted to look beyond location and CRO size. They needed a fair way to compare US and Australian CROs, understand the strengths of different partnership models, and consider cost alongside the study’s operational needs.
We designed and co-ordinated the selection process from initial alignment through RFI, RFP, and bid defense. We assessed each CRO against the same study-specific criteria, giving the sponsor a clear basis for comparing options.
The evaluation led to a different model than appointing a single CRO. An Australian CRO was selected to lead the study in partnership with a US CRO, giving the sponsor access to the capabilities it needed across both regions while supporting cost-effectiveness.
All selection deadlines were met, allowing the sponsor to appoint its CRO partners and achieve first patient in according to the planned study timeline.
What Seuss+ Delivered
Cross-Regional CRO Selection Built Around the Study. We designed a selection process that allowed the sponsor to compare CROs of different sizes across the US and Australia against the needs of the Phase 2 study.
We started by aligning on what mattered most for the trial and defining the criteria that would guide the decision. From there, we managed the RFI and RFP before co-ordinating the bid defense process.
Crucially, the assessment did not assume that one CRO needed to do everything. We considered different partnership models and examined how CROs from the two regions could work together.
This gave the sponsor the evidence needed to select an Australian CRO to lead the study in partnership with a US CRO. The chosen model balanced study requirements, regional capabilities, and cost considerations.
We documented the evaluation and decision-making throughout, creating a clear audit trail and giving internal stakeholders and the board confidence in how we reached the final decision.
The Risk/Challenge
The sponsor needed to select the right CRO partner for a Phase 2 orphan disease CNS study
CROs of different sizes across the US and Australia needed to be compared fairly
The sponsor needed to determine whether a single-CRO or multi-CRO model would better support the study
Cost needed to be considered alongside capability, regional experience, and study requirements
Each potential partner needed to be assessed against consistent criteria
Internal stakeholders and the board needed confidence in the final selection
The evaluation and decision-making needed to be fully documented
CRO selection needed to stay aligned with the planned study start-up timeline
The Results
An Australian CRO was selected to lead the study in partnership with a US CRO
The sponsor gained a data-driven basis for comparing CROs across two regions
CROs of different sizes and different partnership models were assessed against the needs of the study
The selected model combined capabilities from Australia and the US while taking cost-effectiveness into account
All selection deadlines were met
The sponsor achieved first patient in according to the planned study timeline
Internal stakeholders aligned around the selected CRO partnership
The board had clear evidence supporting how the decision had been reached
The CRO evaluation and selection process was fully documented and audit-ready
Sponsor-friendly payment terms and KPIs were negotiated to support CRO accountability
How We Helped
Aligned the selection criteria with the specific needs of the Phase 2 CNS study
Designed a tailored process for comparing CROs across the US and Australia
Managed the RFI process
Developed and managed the RFP
Co-ordinated the bid defense process
Compared CROs of different sizes and regional capabilities
Assessed single-CRO and multi-CRO partnership models
Evaluated how CRO capabilities could be combined across the two regions
Supported the decision to appoint an Australian CRO as study lead in partnership with a US CRO
Managed communications with participating CROs throughout the selection
Documented the evaluation and decision-making to create a clear audit trail
Supported internal and board alignment around the selected partnership model
Supported contract negotiations, including payment terms and KPIs
Kept the selection process aligned with the wider study timeline
Frequently Asked Questions
The right CRO does not always need to come from the sponsor's home market or be the largest provider. Comparing CROs across regions can reveal differences in capabilities, operating models, regional experience, and cost. It can also open up partnership models that may not be obvious at the start of the selection process.
Yes. Depending on the needs of the study, combining CROs can give a sponsor access to complementary capabilities across regions. In this case, the evaluation supported an Australian CRO leading the study in partnership with a US CRO.
We begin by defining what the study actually needs and agreeing on the criteria that matter most. We then use those criteria consistently through the RFI, RFP, and bid defense stages. This gives the sponsor a clearer view of capability, fit, operating model, and commercial considerations, with the decision documented throughout.
Other Related Case Studies
Schedule a consultation now
Key Takeaways
- A small biotech preparing a Phase 2 orphan disease CNS study needed to compare US and Australian CROs of different sizes, weighing cost alongside the study's operational needs.
- Seuss+ ran the selection from initial alignment through RFI, RFP, and bid defense, assessing every CRO against the same study-specific criteria.
- The evaluation looked at both single-CRO and multi-CRO models instead of assuming one CRO had to do everything.
- An Australian CRO was selected to lead the study in partnership with a US CRO, combining capabilities across both regions while supporting cost-effectiveness.
- Every selection deadline was met, first patient in was achieved on the planned timeline, and the decision was documented for the board.
When you compare CROs on what the study actually needs, the answer can look different from the one you expected. Here it was two CROs in two regions, and that combination gave the sponsor the capabilities it needed in both markets.
Comparing CROs across regions?
Book a 30-minute call. We will look at whether a single CRO or a regional partnership would serve your study best.
Book an intro call
